EA2251 trial (ivonescimab): what clinicians have said so far
Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer
- NCT07765433 ↗
- Not yet recruiting
- ECOG-ACRIN Cancer Research Group
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on EA2251 (ivonescimab in advanced biliary tract cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Some of the questions raised in the 9 indexed sources
Automated from all 9 indexed sources (Oct 2026 – Nov 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.
- Whether EA2251 in a US population matches the HARMONi-GI1 findings from a China-only trial
- When EA2251 sites will open and enrolment will begin
- Whether EA2251 can support US approval of ivonescimab in first-line biliary tract cancer, and how soon
Indexed commentary on EA2251 so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 9 posts on X, typically up to 40 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase II/III Randomized Study of Ivonescimab With Gemcitabine and Cisplatin Versus Standard of Care Chemoimmunotherapy in Advanced Biliary Tract Cancer
- Phase
- Phase 2/Phase 3
- Status
- Not yet recruiting
- Conditions
- Locally Advanced Biliary Tract Adenocarcinoma; Locally Advanced Extrahepatic Cholangiocarcinoma; Locally Advanced Intrahepatic Cholangiocarcinoma; Locally Advanced Unresectable Gallbladder Adenocarcinoma; Metastatic Biliary Tract Adenocarcinoma; Metastatic Extrahepatic Cholangiocarcinoma; Metastatic Gallbladder Adenocarcinoma; Metastatic Intrahepatic Cholangiocarcinoma; Stage III Distal Bile Duct Cancer AJCC v8; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IV Distal Bile Duct Cancer AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8; Unresectable Biliary Tract Adenocarcinoma; Unresectable Extrahepatic Cholangiocarcinoma; Unresectable Intrahepatic Cholangiocarcinoma
- Interventions
- Biospecimen Collection; Cisplatin; Computed Tomography; Durvalumab; Gemcitabine Hydrochloride; Ivonescimab; Magnetic Resonance Imaging; Pembrolizumab
- Arms
- Arm A (gemcitabine, cisplatin, durvalumab, pembrolizumab) · Active comparator
- Arm B (gemcitabine, cisplatin, ivonescimab) · Experimental
- Enrollment
- 336 (estimated)
- Primary outcomes
- Overall survival (OS)
- Sponsor
- ECOG-ACRIN Cancer Research Group with National Cancer Institute (NCI)
- Start
- Jan 11, 2027 (estimated)
- Primary completion
- Dec 31, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT07765433 · updated Aug 14, 2026